Combining BRAF and MEK Inhibitors to Treat Melanoma
Ragini Kudchadkar, MD, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.
Clinical Pearls
- Early data has shown that the combination of BRAF and MEK inhibitors improve outcomes compared with single agents in patients with melanoma
- By combining the agents, the mechanism of resistance from the cancer cell is blocked. This allows patients to stay on therapy longer and decreases skin toxicities that are seen in single agent use
- The combination of BRAF and MEK inhibitors will likely become the next standard of care
Related Videos
Related Content
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024Article
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
